Clinical & Scientific

With its lead drug in human trials, ViroMissile hires a seasoned CBO to navigate the competitive oncolytic virus market and secure its future.

The first-ever Wegovy pill is now available via telehealth platform Ro, offering a cash-pay option that could revolutionize access to weight loss drugs.

The biotech firm faces a delisting threat after its equity turned negative. Can recent funding save its Nasdaq spot and its ambitious drug pipeline?

Publishers embrace EdTech as Wiley's content meets Top Hat's AI, promising a future of personalized, data-driven education for millions of students.

With a new name and a laser focus on its lead hemophilia A drug, Metagenomi Therapeutics signals a major shift from platform tech to clinical powerhouse.

With $6.5M CAD in new funding, Montréal's AI4Eyes is set to accelerate the global launch of its all-in-one diagnostic and treatment platform.

NYU Langone and tech firm Tempus are launching a new protocol using serial DNA sequencing and AI to create hyper-personalized cancer treatments.

With new funding, Major Medical Devices is advancing a novel AAA repair device that uses arm access, promising safer procedures and wider patient eligibility.

With new trials in myositis and pediatrics, Cartesian Therapeutics pioneers an outpatient cell therapy, moving beyond cancer to treat chronic autoimmune diseases.

Sanofi deepens its AI partnership with CytoReason in a $16M deal, signaling a major shift in using predictive models to accelerate immunology breakthroughs.

A major pharma giant is betting on artificial intelligence to accelerate cancer drug discovery, a move that could reshape the future of oncology treatment.

The firm is now recruiting for a Phase 1 trial of HWK-007 and has submitted an IND for HWK-016, targeting tough lung, ovarian, and endometrial cancers.

A new partnership aims to bring cutting-edge cancer trials to community clinics, accelerating drug development and expanding patient access to care.

With an expanded Boehringer Ingelheim deal and a new CMO, Enara Bio is set to take its novel 'Dark Antigen' therapy into human trials in 2026.

Replicate Bioscience secures major funding to develop next-gen self-replicating RNA vaccines, aiming for more durable and accessible global health solutions.

A new clinical benchmark published in a Nature journal reveals a Chinese AI is the safest and most effective, challenging Silicon Valley's dominance.

With seasoned executive Adam Rosenberg at the helm, AstronauTx is advancing its novel sleep-focused therapy, backed by major investors, into the Alzheimer's arena.

With enrollment complete for three major trials, MediciNova braces for a transformative year with crucial data expected for its ALS and metabolic disease candidates.

Greenwich LifeSciences execs extend their stock lock-up to 6 years, signaling massive confidence in their breast cancer drug showing an 80% recurrence drop.

In a fierce biotech talent war, Senti Bio's new equity grant for a key hire signals a strategic push for its gene therapy pipeline amid market volatility.